In a multicenter study with a small sample size of 78 patients with breast cancer undergoing doxorubicin and trastuzumab therapy, an early increase in ultrasensitive troponin I (TnI) and myeloperoxidase (MPO) levels offered additive information on the risk of cardiotoxicity. Here, MPO is linked to breast cancer.